Chimeric CD46/DAF molecules reveal a cryptic functional role for SCR1 of DAF in regulating complement activation

被引:9
作者
Christiansen, D
Loveland, B
Kyriakou, P
Lanteri, M
Rubinstein, E
Gerlier, D [1 ]
机构
[1] Fac Med Laennec, VPV, CNRS, UCBL UMR 5537, F-69372 Lyon 08, France
[2] Austin Res Inst, Heidelberg, Vic 3084, Australia
[3] Hop Paul Brousse, INSERM, U268, Villejuif, France
基金
英国医学研究理事会;
关键词
CD46; CD55; C3b deposition; membrane cofactor protein;
D O I
10.1016/S0161-5890(01)00002-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chimeric proteins using membrane cofactor (CD46) and decay accelerating factor (DAF or CD55) were generated to further investigate the functional domains involved in the regulation of human serum complement. Following activation of the classical pathway, the isolated substitution of CD46 SCR III (x 3DAF) exhibited a modest regulatory activity comparable to that of CD46. The isolated substitution of CD46 SCR IV (x 4DAF), and the combined CD46 SCR III + IV substitutions (x 3/4DAF) were essentially as efficient as DAF. No regulation of C3b deposition was observed with the combined CD46 SCR I + II substitutions (x 1/2DAF). When tested after activation of the alternative pathway, both the x 3DAF and x 3/4DAF chimeras failed to regulate C3b deposition, while the x 4DAF chimera still displayed some activity. In contrast to that observed following classical pathway activation, the x 1/2DAF chimera exhibited a similar efficiency to wild type CD46 and DAF in controlling C3b deposition. Using SCR specific antibodies, the regulatory activity of the x 1/2DAF chimera against the alternative pathway was mapped to the first three distal SCR (i.e. DAF 1, DAF 2 and CD46 III). These data demonstrate that several combinations of SCR domains from two related complement regulators can result in functional molecules, and reveal a novel and cryptic functional role for DAF SCR1. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:687 / 696
页数:10
相关论文
共 51 条
[11]  
COYNE KE, 1992, J IMMUNOL, V149, P2906
[12]   Pigs express multiple forms of decay-accelerating factor (CD55), all of which contain only three short consensus repeats [J].
de la Lastra, JMP ;
Harris, CL ;
Hinchliffe, SJ ;
Holt, DS ;
Rushmere, NK ;
Morgan, BP .
JOURNAL OF IMMUNOLOGY, 2000, 165 (05) :2563-2573
[13]  
Devaux P, 1999, EUR J IMMUNOL, V29, P815
[14]   Immune evasion of tumor cells using membrane-bound complement regulatory proteins [J].
Gorter, A ;
Meri, S .
IMMUNOLOGY TODAY, 1999, 20 (12) :576-582
[15]  
GOTZE O, 1971, J EXP MED, V134, pS90
[16]   THE REGULATORS OF COMPLEMENT ACTIVATION (RCA) GENE-CLUSTER [J].
HOURCADE, D ;
HOLERS, VM ;
ATKINSON, JP .
ADVANCES IN IMMUNOLOGY, 1989, 45 :381-416
[17]   ANALYSIS OF THE SHORT CONSENSUS REPEATS OF HUMAN-COMPLEMENT FACTOR-B BY SITE-DIRECTED MUTAGENESIS [J].
HOURCADE, DE ;
WAGNER, LM ;
OGLESBY, TJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (34) :19716-19722
[18]   Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding [J].
Hsu, EC ;
Dorig, RE ;
Sarangi, F ;
Marcil, A ;
Iorio, C ;
Richardson, CD .
JOURNAL OF VIROLOGY, 1997, 71 (08) :6144-6154
[19]   DIVERSITY OF SITES FOR MEASLES-VIRUS BINDING AND FOR INACTIVATION OF COMPLEMENT C3B AND C4B ON MEMBRANE COFACTOR PROTEIN CD46 [J].
IWATA, K ;
SEYA, T ;
YANAGI, Y ;
PESANDO, JM ;
JOHNSON, PM ;
OKABE, M ;
UEDA, S ;
ARIGA, H ;
NAGASAWA, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (25) :15148-15152
[20]  
JOHNSTONE RW, 1993, IMMUNOLOGY, V79, P341